Postmenopausal hormone therapy
- 26 April 2007
- Vol. 334 (7599) , 860-861
- https://doi.org/10.1136/bmj.39188.594282.80
Abstract
Footnotes Competing interests: DG has received research support from Berlex, Bionovo, Eli Lilly, and Pfizer. EB-C has received research support from NIH, Amgen, Lilly, Merck, Wyeth, Proctor and Gamble, Roche, and GlaxoSmithKline. Provenance and peer review: Commissioned; not externally peer reviewed.Keywords
This publication has 8 references indexed in Scilit:
- Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since MenopauseJAMA, 2007
- Estrogen and progestogen use in peri- and postmenopausal womenMenopause, 2007
- Management of menopause-related symptoms.2005
- Conjugated Equine Estrogens and Incidence of Probable Dementia and Mild Cognitive Impairment in Postmenopausal WomenWomen's Health Initiative Memory StudyJAMA, 2004
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal WomenJAMA, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Current methods of the U.S. Preventive Services Task ForceAmerican Journal of Preventive Medicine, 2001